首頁 > 市場調查報告書 > 醫療設備

e保健遠距離醫療

市場調查報告書

商品編碼

1643924

全球遠距腫瘤學市場 - 2025-2032

Global Teleoncology Market - 2025-2032

出版日期: 2025年01月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球遠端腫瘤市場達到47億美元，預計2032年將達到150.3億美元，2024-2032年預測期間複合年成長率為15.7%。

遠距腫瘤學是指遠距醫療在腫瘤學中的應用，涉及透過虛擬平台提供診斷、治療和監測等腫瘤學服務。遠距腫瘤學使生活在偏遠地區的患者能夠以較低的成本獲得準確的診斷、做出臨床決策並獲得精確的護理。遠距腫瘤學減輕了偏遠患者的經濟負擔，消除了經常去醫院就診的需要。

主要市場參與者在癌症護理中擴大採用和實施遠距醫療以及現代醫療保健服務的技術進步，預計將在預測期內推動市場成長發揮至關重要的作用。

市場動態：

驅動程式和限制

遠距醫療在癌症護理中的採用和實施不斷增加

癌症護理中遠距醫療的持續採用和實施是預測期內市場成長的一個主要因素。 COVID-19 大流行顯然影響了向患者提供醫療保健的方式。遠端監控、遠距醫療和線上諮詢已受到關注，其重要性在大流行後日益成長。大流行後，美國許多知名的癌症診所已經開始虛擬諮詢、遠端監測和護理。

遠距醫療實際上拉近了醫生和患者的距離，並已成為向偏遠或農村地區患者提供護理的主要媒介。

根據 USA Facts 報導，遠距醫療的採用率在美國急劇上升。醫療保險受益人的遠距醫療就診次數從約 500 萬增加到超過 5,300 萬，大多數醫生計劃進一步實施遠距醫療實踐。

美國的幾個癌症護理中心也開始提供虛擬服務，其中，線上諮詢在農村地區的腫瘤患者中佔據了很大佔有率。

遠距醫療的實施也消除了旅行費用，減輕了農村患者的經濟負擔。例如，2023 年 JAMA 網路上發表的一項研究評估了與實施遠距醫療相關的成本降低，報告稱每次就診平均節省 147 美元至 186 美元。

在預測期內，需求預計將持續上升，推動市場成長。

缺乏意識和技術差距

農村地區對遠距腫瘤學的需求較高，居住在這些地區的患者群體是遠距腫瘤學服務的主要目標。遠端腫瘤學的實施與使用具有高速網際網路連接的軟體和現代電子設備有關。這可能對老年族群和存在技術差距的患者構成挑戰。患者可能會覺得這個過程很麻煩，可能會猶豫是否採用這種新穎的照護方法，而更喜歡透過醫師就診的傳統照護方式。

因此，儘管其他已開發地區的需求不斷成長，但在世界某些地區，遠距腫瘤學的採用仍受到質疑。此外，虛擬護理對癌症患者的選擇有限。癌症患者必須接受頻繁的篩檢測試，以評估癌症的臨床分期並檢查治療的預後。

虛擬地實現這一點的唯一方法是，如果患者訪問最近的診斷中心，生成的放射影像將發送給虛擬地對患者進行治療的相應醫生。

由於農村地區缺乏適當的診斷設施，這一過程再次受到限制。有些患者可能會在整個過程中感到模糊。而且，各州的監管政策不同，採用的情況也可能因州而異。遠距腫瘤學服務的報銷政策和承保範圍也可能有所不同。這可能會被動影響遠距腫瘤學服務的採用。

所有這些因素都可能限制預測期內的市場成長。

Teleoncology refers to the application of telemedicine to oncology, which involves delivering oncology services such as diagnosis, treatment, and monitoring via virtual platforms. Teleoncology enables patients living in remote areas to get accurate diagnoses, make clinical decisions, and get precise care at lower costs. Teleoncology reduces the economic burden on remote patients, eliminating the need for frequent hospital visits.

The rising adoption and implementation of telemedicine in cancer care and technological advancements in modern healthcare services by major market players are expected to play a crucial role in driving market growth in the forecast period.

Market Dynamics: Drivers & Restraints

The Rising Adoption and Implementation of Telemedicine in Cancer Care

The rising adoption and implementation of telemedicine in cancer care is a major factor contributing to the market growth in the forecast period. The COVID-19 pandemic has clearly affected the way healthcare is delivered to patients. Remote monitoring, telemedicine, and online consultations have gained traction, and their importance is ever-growing post-pandemic. Post-pandemic many reputed cancer clinics across the U.S. have started virtual consultations, remote monitoring, and care.

Telemedicine has brought physicians and patients closer virtually, and it has become a major medium for care delivery to patients living in remote or rural areas.

According to USA Facts, the adoption of telehealth has risen drastically in the United States. Telehealth visits have increased from about 5 million to more than 53 million among Medicare recipients and the majority of physicians plan to implement telemedicine practices going further.

Several cancer care delivery centers in the U.S. have also initiated delivering their services virtually, and among these services, online consultations have a major share for oncology patients living in rural areas.

The implementation of telehealth has also reduced the financial burden imposed on rural patients by eliminating the cost of travel. For instance, a research study published in the JAMA network in 2023, which has evaluated the cost reductions associated with the implementation of telehealth has reported an average saving between US$147 to US$186 per visit.

In the forecast period, the demand is expected to continuously rise, fuelling the market growth.

Lack of Awareness and Technological Gaps

The need for Teleoncology is higher in rural areas and the patient population living in these parts is the major target for teleoncology services. The implementation of Teleoncology is linked with the use of software and modern electronic devices with high-speed internet connectivity. This may pose a challenge to the elderly population and patients with technological gaps. Patients may feel this process to be cumbersome and may hesitate to adopt this novel method of care, and rather prefer the traditional way of care through physician visits.

Hence the adoption of teleoncology becomes questionable in certain parts of the world, despite the growing demand in the other well-developed regions. Moreover, virtual care has limited options for cancer patients. Cancer patients must undergo frequent screening tests to assess the clinical stage of cancer and to check the prognosis of the treatment.

The only way this can be done virtually is if the patient visits the nearest diagnostic center, the radiology images generated will be sent to the corresponding physician who is addressing the patient virtually.

This process again is limited by the lack of proper diagnostic facilities in rural areas. Some patients may feel ambiguity in this entire process. Moreover, the regulatory policies vary from state to state, and the adoption may vary according to the state. The reimbursement policies and extent of coverage for Teleoncology services may also vary. This may passively impact the adoption of teleoncology services.

All these factors may restrain the market growth in the forecast period.

Segment Analysis

The global teleoncology market is segmented based on component, cancer type, application, and region.

Breast cancer is the cancer type segment that is expected to dominate the market.

Among different cancers that are affecting patients, breast cancer is one of the most prevalent cancers.

For instance, As per the recent statistics published by the Global Cancer Observatory, in 2022, there are approximately 2.3 million new breast cancer cases reported across the world. Ranking among the top most incident cancer cases. It is estimated that in 2025, the number of breast cancer cases incidence will rise to 2.5 million, and in 2030, the incidence will reach 2.7 million cases. This alarming rise in breast cancer is a major contributing factor to its dominance in the teleoncology market.

As the number of patients with breast cancer is higher among other cancers, the patient population opting for teleoncology services is also expected to be higher. For instance, according to a study published in Nature Journal in 2023, the implementation of telemedicine is majorly recorded for breast cancer followed by lung cancer, head, and neck cancers, brain cancer, and others, and among the telemedicine, teleconsultation was the most commonly deployed application with a share of 60%.

Moreover, due to care disparities among urban and rural populations, breast cancer patients in rural areas have higher mortality as compared to urban breast cancer patients. The disparities arise from a lack of care physicians, advanced diagnostic facilities, and a lower rate of early cancer diagnosis. For instance, a recent study published in the National Center for Biotechnology Information in 2021, has stated that the 10-year risk of breast cancer mortality is higher among rural population i.e., 17.1%, which is higher than that of mortality of breast cancer patients living in metropolitan areas which is 14.6%.

The implementation of teleoncology services and the launch of remote digitalized diagnostic equipment in rural areas will provide an opportunity to increase the survival rate, and also reduce the financial burden imposed due to frequent physician visits for breast cancer patients.

Geographical Analysis

North America is expected to hold a significant share of the teleoncology market.

North America currently holds a significant market share in the teleoncology market due to various factors including, the advanced healthcare infrastructure, technologically advanced states, high awareness of telemedicine, and the rising prevalence of cancer. For instance, as per the International Agency for Research on Cancer projections, nearly 2.60 million new cancer cases were reported in North America, and by 2040, the incidence is expected to reach 3.60 million. This rising prevalence combined with the advanced healthcare landscape positions North America as the market leader in the global teleoncology market.

The region has higher investments in telehealth platforms to significantly improve patient access to medical care. Moreover, governments in North America are proactively supporting the integration of telemedicine, encompassing teleoncology, through diverse policies and initiatives. One significant example is the Centers for Medicare & Medicaid Services (CMS) in the U.S., which has broadened its reimbursement policies for telehealth services. This expansion includes teleoncology, thereby enhancing patient accessibility to these advanced healthcare services.

Competitive Landscape

The major global players in the teleoncology market are Teladoc Health, Inc., American Well, Moffitt Cancer Center, Eagle Telemedicine., Intermountain Health, Klara Technologies, Inc., DocPanel Technologies, Inc., OurExpertDoc, Cancerdocs and OncoHealth. among others.

Emerging Players

The emerging players in the teleoncology market include Proto Inc., Shemha Health, Belong. Life, among others

Key Developments

In September 2024, Proto Inc. in collaboration with West Cancer Center & Research Institute launched the first holographic doctor-patient visits at UC Berkeley's forum. This innovation provides patients living in remote areas access to specialized oncology care.
In April 2023, Shemha Health launched a new Telemedicine platform called PrOPA (Precision Oncology Patient Advice). PrOPA is a large-scale solution designed to provide virtual end-to-end solutions for cancer patients ranging from initial diagnostics to treatment. In PrOPA, top-selected healthcare professionals consult to discuss and formulate specific guidelines for diagnosis, treatment, and patient monitoring.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global teleoncology market report would provide approximately 62 tables, 57 figures, and 195 pages.

Target Audience 2023

Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Component
3.2. Snippet by Cancer Type
3.3. Snippet by Application
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. The Rising Adoption and Implementation of Telemedicine in Cancer Care
- 4.1.3. Technological Advancements in Remote Patient Monitoring
4.2. Restraints
- 4.2.1. Lack of Awareness and Technological Gaps
- 4.2.2. XX
4.3. Opportunities
4.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Patent Analysis
5.4. Regulatory Analysis
5.5. Technology and Trend Analysis

6. By Component

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 6.1.2. Market Attractiveness Index, By Component
6.2. Software*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Hardware
6.4. Services

7. By Cancer Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Breast Cancer*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Lung Cancer
7.4. Colorectal Cancer
7.5. Prostate Cancer
7.6. Bladder Cancer
7.7. Liver Cancer
7.8. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Remote Patient Monitoring*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Medical Second Opinions
8.4. Patient Consultations
8.5. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

11.1. Teladoc Health, Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.3. Financial Overview
  - 11.1.3.1. Company Revenue's
  - 11.1.3.2. Geographical Revenue Shares
  - 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
  - 11.1.4.1. Mergers & Acquisitions
  - 11.1.4.2. Key Product Development Activities
  - 11.1.4.3. Regulatory Approvals etc.
- 11.1.5. SWOT Analysis
11.2. American Well
11.3. Moffitt Cancer Center
11.4. Eagle Telemedicine.
11.5. Intermountain Health
11.6. Klara Technologies, Inc.
11.7. DocPanel Technologies, Inc.
11.8. OurExpertDoc
11.9. Cancerdocs
11.10. OncoHealth.
Similar data will be provided for each market player.